Cover Kidney News
Volume/Issue:
Volume 6: Issue 1
Page:
10
Publication Date:
01 Jan 2014
Online Publication Date:
31 Aug 2015
  • 1

    Opgenorth TJ . Endothelin receptor antagonism. Adv Pharmacol 1995; 33:1–65.

  • 2

    Kohan DE , et al.. Physiology of endothelin and the kidney. Compr Physiol 2011; 1:883–919.

  • 3

    Dhaun N , Goddard J , Webb DJ . The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006; 17:943–955.

  • 4

    Wenzel RR , et al.. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009; 20:655–664.

  • 5

    Mann JF , et al.. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527–535.

  • 6

    Kohan DE , et al.. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011; 22:763–772.

  • 7

    J Am Soc Nephrol, in press.

  • 8

    Bakris GL , et al.. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010; 56:824–830.

    • PubMed
    • Search Google Scholar
    • Export Citation

Learning from Failure: New Therapy for Diabetic Nephropathy and Beyond?

David M. Pollock
Search for other papers by David M. Pollock in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 6: Issue 1
Publication Date:
01 Jan 2014
Page:
10
Restricted access

Which holds more promise for halting the progression of chronic kidney disease: the renin-angiotension system blockade or endothelin antagonists? Two experts weigh in.

Save